Tumor microenvironment signaling and therapeutics in cancer progression.
3D-model
cancer therapy
gut microbiota
immune signaling
metabolism
signaling
tumor microenvironment
Journal
Cancer communications (London, England)
ISSN: 2523-3548
Titre abrégé: Cancer Commun (Lond)
Pays: United States
ID NLM: 101723675
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
22
02
2023
received:
24
10
2022
accepted:
20
03
2023
medline:
15
5
2023
pubmed:
4
4
2023
entrez:
3
4
2023
Statut:
ppublish
Résumé
Tumor development and metastasis are facilitated by the complex interactions between cancer cells and their microenvironment, which comprises stromal cells and extracellular matrix (ECM) components, among other factors. Stromal cells can adopt new phenotypes to promote tumor cell invasion. A deep understanding of the signaling pathways involved in cell-to-cell and cell-to-ECM interactions is needed to design effective intervention strategies that might interrupt these interactions. In this review, we describe the tumor microenvironment (TME) components and associated therapeutics. We discuss the clinical advances in the prevalent and newly discovered signaling pathways in the TME, the immune checkpoints and immunosuppressive chemokines, and currently used inhibitors targeting these pathways. These include both intrinsic and non-autonomous tumor cell signaling pathways in the TME: protein kinase C (PKC) signaling, Notch, and transforming growth factor (TGF-β) signaling, Endoplasmic Reticulum (ER) stress response, lactate signaling, Metabolic reprogramming, cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) and Siglec signaling pathways. We also discuss the recent advances in Programmed Cell Death Protein 1 (PD-1), Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA4), T-cell immunoglobulin mucin-3 (TIM-3) and Lymphocyte Activating Gene 3 (LAG3) immune checkpoint inhibitors along with the C-C chemokine receptor 4 (CCR4)- C-C class chemokines 22 (CCL22)/ and 17 (CCL17), C-C chemokine receptor type 2 (CCR2)- chemokine (C-C motif) ligand 2 (CCL2), C-C chemokine receptor type 5 (CCR5)- chemokine (C-C motif) ligand 3 (CCL3) chemokine signaling axis in the TME. In addition, this review provides a holistic understanding of the TME as we discuss the three-dimensional and microfluidic models of the TME, which are believed to recapitulate the original characteristics of the patient tumor and hence may be used as a platform to study new mechanisms and screen for various anti-cancer therapies. We further discuss the systemic influences of gut microbiota in TME reprogramming and treatment response. Overall, this review provides a comprehensive analysis of the diverse and most critical signaling pathways in the TME, highlighting the associated newest and critical preclinical and clinical studies along with their underlying biology. We highlight the importance of the most recent technologies of microfluidics and lab-on-chip models for TME research and also present an overview of extrinsic factors, such as the inhabitant human microbiome, which have the potential to modulate TME biology and drug responses.
Identifiants
pubmed: 37005490
doi: 10.1002/cac2.12416
pmc: PMC10174093
doi:
Substances chimiques
Receptors, Chemokine
0
Chemokines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
525-561Informations de copyright
© 2023 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center.
Références
Mol Cancer. 2021 Feb 5;20(1):28
pubmed: 33546704
J Immunother Cancer. 2021 Jun;9(6):
pubmed: 34083417
Nat Rev Cancer. 2007 Apr;7(4):281-94
pubmed: 17384583
Oncotarget. 2016 May 31;7(22):32532-42
pubmed: 27081038
J Invest Dermatol. 2014 Apr;134(4):975-983
pubmed: 24192715
Mol Carcinog. 2018 Aug;57(8):1017-1029
pubmed: 29637628
Front Immunol. 2019 Apr 11;10:766
pubmed: 31031762
Mol Cancer Ther. 2013 Jun;12(6):831-43
pubmed: 23729400
Cancer Cell. 2017 May 8;31(5):711-723.e4
pubmed: 28486109
Signal Transduct Target Ther. 2021 Aug 20;6(1):312
pubmed: 34417437
Blood. 2007 May 1;109(9):3812-9
pubmed: 17255361
J Clin Oncol. 2021 Feb 20;39(6):619-630
pubmed: 33439693
Cancer Biol Ther. 2007 Nov;6(11):1691-9
pubmed: 18032930
Nature. 2019 Oct;574(7777):264-267
pubmed: 31578522
Breast Cancer Res. 2016 Jan 08;18(1):5
pubmed: 26747277
Front Immunol. 2022 Jul 26;13:956090
pubmed: 35958563
Oncoimmunology. 2013 Nov 1;2(11):e26383
pubmed: 24404426
Nature. 2010 Feb 11;463(7282):E6-7
pubmed: 20147986
Adv Drug Deliv Rev. 2014 Dec 15;79-80:68-78
pubmed: 25017040
Neuro Oncol. 2015 May;17(5):708-17
pubmed: 25762461
Cancer Res. 2009 Mar 1;69(5):2000-9
pubmed: 19244125
Cell Rep. 2018 Apr 3;23(1):39-49
pubmed: 29617671
J Immunol. 2012 Jun 15;188(12):5887-97
pubmed: 22586032
MAbs. 2019 Aug/Sep;11(6):1139-1148
pubmed: 31242068
Ther Adv Med Oncol. 2019 Jun 21;11:1758835919854238
pubmed: 31258629
Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):129-39
pubmed: 16377233
Exp Cell Res. 2016 Apr 10;343(1):73-81
pubmed: 26597760
Cell Signal. 2014 Feb;26(2):287-94
pubmed: 24240056
Cancer Discov. 2021 May;11(5):1212-1227
pubmed: 33372007
Signal Transduct Target Ther. 2020 Aug 25;5(1):166
pubmed: 32843638
Trends Cell Biol. 2021 Nov;31(11):940-950
pubmed: 34272133
EBioMedicine. 2019 Mar;41:370-383
pubmed: 30799198
J Exp Med. 2013 Feb 11;210(2):321-37
pubmed: 23359069
Biochem Biophys Res Commun. 2018 May 5;499(2):374-380
pubmed: 29577899
Biochem J. 2021 Sep 17;478(17):3331-3349
pubmed: 34435619
Cell Commun Signal. 2022 Jan 28;20(1):14
pubmed: 35090497
EMBO Mol Med. 2020 Jun 8;12(6):e11571
pubmed: 32391629
Front Immunol. 2020 Jan 17;10:2989
pubmed: 32010123
J Clin Invest. 1996 Nov 1;98(9):2018-26
pubmed: 8903320
Nat Rev Cancer. 2019 Feb;19(2):65-81
pubmed: 30647431
Front Pharmacol. 2018 Jan 23;9:6
pubmed: 29410625
Immunol Rev. 2012 Sep;249(1):43-58
pubmed: 22889214
Nat Med. 2018 Aug;24(8):1178-1191
pubmed: 29942093
Front Immunol. 2020 Oct 21;11:568931
pubmed: 33193345
Front Immunol. 2017 Nov 17;8:1553
pubmed: 29209314
Biochem Biophys Res Commun. 2006 Jul 14;345(4):1440-5
pubmed: 16725108
Mol Cell. 2020 Mar 5;77(5):937-950.e6
pubmed: 31926851
J Exp Med. 1999 Nov 15;190(10):1417-26
pubmed: 10562317
Cell Death Differ. 2017 Jun;24(6):1100-1110
pubmed: 28452996
Signal Transduct Target Ther. 2021 Jan 8;6(1):8
pubmed: 33414388
Cell. 2018 Apr 5;173(2):515-528.e17
pubmed: 29625057
Cancer Res. 2014 Jun 15;74(12):3199-204
pubmed: 24830719
Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19444-9
pubmed: 19033462
Sci Immunol. 2017 Nov 17;2(17):
pubmed: 29150439
Int J Environ Res Public Health. 2018 Aug 14;15(8):
pubmed: 30110974
Adv Biol (Weinh). 2021 Sep;5(9):e2100758
pubmed: 34170628
Clin Cancer Res. 2021 Jul 1;27(13):3620-3629
pubmed: 33883177
Trends Mol Med. 2021 Mar;27(3):207-219
pubmed: 33199209
Cancer Cell. 2009 Aug 4;16(2):91-102
pubmed: 19647220
Wound Repair Regen. 2000 Sep-Oct;8(5):353-60
pubmed: 11115148
Signal Transduct Target Ther. 2022 Mar 24;7(1):95
pubmed: 35332121
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Biochem Mol Biol Int. 1998 Mar;44(3):523-8
pubmed: 9556213
N Engl J Med. 2004 Jun 3;350(23):2335-42
pubmed: 15175435
Biomaterials. 2018 Jul;170:37-48
pubmed: 29653286
Nat Commun. 2020 Jun 26;11(1):3259
pubmed: 32591509
Transl Cancer Res. 2020 Nov;9(11):6811-6819
pubmed: 35117290
Science. 2009 Jun 12;324(5933):1457-61
pubmed: 19460966
J Clin Invest. 2004 Mar;113(5):774-83
pubmed: 14991076
Trends Biochem Sci. 2016 Jun;41(6):519-531
pubmed: 27085506
Cancer Immunol Immunother. 2001 Dec;50(10):533-8
pubmed: 11776375
J Biol Chem. 2003 Jun 6;278(23):20915-24
pubmed: 12665508
Science. 2019 May 10;364(6440):558-566
pubmed: 31000591
Blood. 2015 Mar 19;125(12):1847-8
pubmed: 25792728
Blood. 2006 Mar 1;107(5):2013-21
pubmed: 16278308
Trends Cancer. 2017 Mar;3(3):169-180
pubmed: 28393116
Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7
pubmed: 24277834
Cancer Cell. 2014 Jun 16;25(6):735-47
pubmed: 24856585
Annu Rev Immunol. 2020 Apr 26;38:365-395
pubmed: 31986070
Annu Rev Biochem. 2011;80:71-99
pubmed: 21495850
Front Immunol. 2021 Mar 29;12:654960
pubmed: 33859648
Bone Res. 2018 Jan 31;6:2
pubmed: 29423331
Nat Rev Immunol. 2021 Sep;21(9):548-569
pubmed: 33833439
Cancer Lett. 2007 Jul 8;252(1):86-92
pubmed: 17257744
FEMS Microbiol Ecol. 2008 Dec;66(3):487-95
pubmed: 18537837
Nat Rev Drug Discov. 2019 Nov;18(12):899-900
pubmed: 31780841
Oncotarget. 2017 Dec 31;9(6):6659-6677
pubmed: 29467918
MAbs. 2016 Nov/Dec;8(8):1598-1605
pubmed: 27610476
Drug Resist Updat. 2020 Dec;53:100715
pubmed: 32679188
J Immunol. 1998 Oct 15;161(8):4058-65
pubmed: 9780176
Front Immunol. 2021 Feb 25;12:602277
pubmed: 33717083
Naunyn Schmiedebergs Arch Pharmacol. 2021 Mar;394(3):481-490
pubmed: 33052427
Oncol Lett. 2019 Mar;17(3):3055-3065
pubmed: 30867734
Nat Rev Drug Discov. 2012 Dec;11(12):937-57
pubmed: 23197040
Nat Med. 2009 Jun;15(6):701-6
pubmed: 19398967
J Exp Med. 1997 Nov 17;186(10):1645-53
pubmed: 9362525
Nat Rev Cancer. 2021 Jan;21(1):51-63
pubmed: 33177705
Prog Tumor Res. 2015;42:55-66
pubmed: 26382943
Pharmacol Res. 2020 Sep;159:104980
pubmed: 32504832
Cell Rep. 2019 Jun 11;27(11):3315-3330.e7
pubmed: 31189114
Cancer Immunol Res. 2022 Jun 3;10(6):770-784
pubmed: 35413115
Nature. 2014 Sep 25;513(7519):559-63
pubmed: 25043024
Biomark Res. 2013 Jul 18;1(1):23
pubmed: 24252593
Cancers (Basel). 2019 Jan 03;11(1):
pubmed: 30609850
Tumour Biol. 2016 Feb;37(2):1889-99
pubmed: 26323258
J Immunol. 2005 May 1;174(9):5766-73
pubmed: 15843579
Trends Pharmacol Sci. 2022 Aug;43(8):686-700
pubmed: 35534356
Clin Cancer Res. 2011 Dec 15;17(24):7732-42
pubmed: 22028492
Am J Physiol Heart Circ Physiol. 2006 Jun;290(6):H2528-34
pubmed: 16399861
PLoS One. 2014 Jan 31;9(1):e83786
pubmed: 24497917
Gut. 2022 Jul;71(7):1412-1425
pubmed: 35277453
Cell Metab. 2008 Jan;7(1):11-20
pubmed: 18177721
Eur J Immunol. 2008 Jan;38(1):40-7
pubmed: 18095376
Nat Commun. 2019 May 9;10(1):2123
pubmed: 31073180
Cancers (Basel). 2015 Dec 11;7(4):2443-58
pubmed: 26690480
Cancer Discov. 2021 Apr;11(4):933-959
pubmed: 33811125
Genes Dev. 2004 Oct 15;18(20):2474-8
pubmed: 15466159
Lab Chip. 2015 Nov 7;15(21):4114-27
pubmed: 26334370
Cancer Immunol Res. 2019 Feb;7(2):335-346
pubmed: 30563827
Stem Cell Res Ther. 2021 Jan 25;12(1):81
pubmed: 33494834
Nature. 2020 Apr;580(7802):269-273
pubmed: 32106218
Nat Rev Immunol. 2009 Mar;9(3):162-74
pubmed: 19197294
J Clin Oncol. 2017 May 10;35(14):1561-1569
pubmed: 28350521
Front Cell Dev Biol. 2021 May 31;9:683940
pubmed: 34136492
Front Cell Dev Biol. 2021 Feb 04;9:613534
pubmed: 33614646
Clin Cancer Res. 2014 Feb 15;20(4):926-937
pubmed: 24277449
Glycobiology. 2016 Feb;26(2):111-28
pubmed: 26518624
J Cell Biol. 2013 Nov 25;203(4):615-27
pubmed: 24247433
J Exp Med. 2011 Sep 26;208(10):2005-16
pubmed: 21930765
Sci Transl Med. 2020 Oct 7;12(564):
pubmed: 33028706
Cell. 2015 Jul 30;162(3):540-51
pubmed: 26232224
Mol Cancer. 2018 Jan 11;17(1):5
pubmed: 29325547
Curr Drug Targets. 2010 Aug;11(8):1000-17
pubmed: 20426765
PLoS One. 2009 Nov 23;4(11):e7965
pubmed: 19956757
Sci Transl Med. 2018 Mar 14;10(432):
pubmed: 29540614
IUBMB Life. 2009 Oct;61(10):929-39
pubmed: 19787707
Nat Cell Biol. 2018 Jul;20(7):775-781
pubmed: 29941933
J Clin Invest. 2020 Jul 1;130(7):3865-3884
pubmed: 32324593
Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16420-16429
pubmed: 31371506
Biochem Biophys Res Commun. 1998 Aug 19;249(2):444-8
pubmed: 9712716
Arch Pharm Res. 2019 Feb;42(2):150-158
pubmed: 30756310
J Immunol. 2010 Jun 1;184(11):6545-51
pubmed: 20421648
Front Oncol. 2019 Apr 30;9:305
pubmed: 31114753
Carcinogenesis. 1987 Sep;8(9):1343-6
pubmed: 3621472
Immunity. 2019 Dec 17;51(6):1059-1073.e9
pubmed: 31757674
Neuro Oncol. 2011 Jan;13(1):132-42
pubmed: 20980335
Front Immunol. 2013 Jan 17;3:423
pubmed: 23335926
Clin Cancer Res. 2015 Jun 15;21(12):2753-62
pubmed: 25762343
Proc Natl Acad Sci U S A. 2021 Jul 27;118(30):
pubmed: 34301886
Trends Cancer. 2020 Feb;6(2):160-171
pubmed: 32061305
Oncoimmunology. 2015 Oct 29;5(3):e1091554
pubmed: 27141352
Cancer. 1973 Oct;32(4):735-43
pubmed: 4127428
Nat Rev Cancer. 2018 Jun;18(6):359-376
pubmed: 29700396
J Clin Invest. 2011 Feb;121(2):800-8
pubmed: 21266774
Pharmacol Ther. 2015 Sep;153:107-24
pubmed: 26073310
Hypoxia (Auckl). 2017 Apr 11;5:21-32
pubmed: 28443291
Front Immunol. 2020 Dec 08;11:600000
pubmed: 33363541
Nat Rev Cancer. 2019 Apr;19(4):215-227
pubmed: 30867580
Nat Cell Biol. 2016 Oct;18(10):1090-101
pubmed: 27617932
Indian J Med Res. 2013 Nov;138(5):808-14
pubmed: 24434333
J Clin Invest. 2006 Jul;116(7):1955-62
pubmed: 16794736
Nat Commun. 2017 Nov 23;8(1):1747
pubmed: 29170511
Metabolites. 2017 May 20;7(2):
pubmed: 28531108
Blood. 2012 Jun 14;119(24):5772-81
pubmed: 22538852
Int J Cancer. 2008 May 15;122(10):2286-93
pubmed: 18224687
Nature. 2018 Jan 25;553(7689):467-472
pubmed: 29342134
Clin Cancer Res. 2011 Mar 15;17(6):1382-93
pubmed: 21257720
ESMO Open. 2019 Jun 12;4(Suppl 3):e000497
pubmed: 31275616
J Exp Clin Cancer Res. 2019 Sep 13;38(1):403
pubmed: 31519198
Cells. 2021 Feb 24;10(3):
pubmed: 33668200
J Clin Invest. 2011 Jun;121(6):2350-60
pubmed: 21555851
J Clin Oncol. 2017 Jan;35(1):124-125
pubmed: 27646950
Nat Immunol. 2003 Jul;4(7):670-9
pubmed: 12796776
Trends Immunol. 2018 Nov;39(11):900-920
pubmed: 30392721
Lab Chip. 2018 Jan 16;18(2):249-270
pubmed: 29143053
Genes Dis. 2019 Oct 23;7(2):185-198
pubmed: 32215288
Biochem Biophys Res Commun. 2000 Mar 5;269(1):279-83
pubmed: 10694513
J Immunol. 2009 Feb 1;182(3):1746-55
pubmed: 19155524
Nat Metab. 2021 Jan;3(1):21-32
pubmed: 33398194
Nature. 2020 Oct;586(7827):133-138
pubmed: 32728212
Clin Cancer Res. 2015 Jan 1;21(1):60-7
pubmed: 25231399
Clin Cancer Res. 2015 Oct 1;21(19):4327-36
pubmed: 26429981
Nat Commun. 2021 May 12;12(1):2746
pubmed: 33980853
Eur J Cancer. 2010 Nov;46(16):2926-35
pubmed: 20797845
Commun Biol. 2021 May 14;4(1):581
pubmed: 33990697
Trends Cancer. 2021 Mar;7(3):249-264
pubmed: 33218948
Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10166-71
pubmed: 20534575
BMC Cancer. 2009 Jul 30;9:263
pubmed: 19643020
Invest New Drugs. 2020 Feb;38(1):99-110
pubmed: 30825104
Cancer Res. 2011 Feb 1;71(3):661-5
pubmed: 21148486
J Exp Clin Cancer Res. 2019 Feb 4;38(1):50
pubmed: 30717766
Oncoimmunology. 2018 May 7;7(7):e1440169
pubmed: 29900044
J Control Release. 2018 Mar 28;274:1-8
pubmed: 29382546
Cancer Cell. 2019 Jul 8;36(1):6-16
pubmed: 31287993
EMBO J. 2017 May 15;36(10):1302-1315
pubmed: 28420743
Cancer Immunol Res. 2019 Mar;7(3):476-486
pubmed: 30659052
Cell Metab. 2019 Aug 6;30(2):290-302.e5
pubmed: 31204281
Cancer Gene Ther. 2022 Jan;29(1):10-21
pubmed: 33603130
Proc Natl Acad Sci U S A. 2017 Jan 17;114(3):580-585
pubmed: 28049847
Nature. 2019 Oct;574(7776):45-56
pubmed: 31578484
Trends Cancer. 2022 Oct;8(10):839-854
pubmed: 35624002
Front Oncol. 2020 Feb 12;10:120
pubmed: 32117767
Front Immunol. 2022 Jul 22;13:925985
pubmed: 35936003
Int J Mol Sci. 2021 May 24;22(11):
pubmed: 34073823
Cancer Sci. 2017 Apr;108(4):574-580
pubmed: 28188673
Front Cell Dev Biol. 2020 Dec 09;8:608747
pubmed: 33425916
Acta Pharm Sin B. 2015 Sep;5(5):378-89
pubmed: 26579469
Cell. 2015 May 7;161(4):933-45
pubmed: 25957691
Oncogene. 2017 Apr;36(15):2074-2084
pubmed: 27748760
Cell Stem Cell. 2019 Jan 3;24(1):25-40
pubmed: 30595497
Science. 2020 May 29;368(6494):973-980
pubmed: 32467386
EBioMedicine. 2020 Dec;62:103040
pubmed: 33166791
Chem Soc Rev. 2017 Apr 18;46(8):2237-2271
pubmed: 28319221
Dis Esophagus. 2010 Jul;23(5):422-9
pubmed: 20002703
Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):721-6
pubmed: 11805327
Am J Cancer Res. 2021 Aug 15;11(8):3777-3793
pubmed: 34522449
Lancet. 2019 Aug 10;394(10197):478-487
pubmed: 31229240
J Exp Med. 2003 Jun 2;197(11):1525-35
pubmed: 12782715
Nat Immunol. 2018 Dec;19(12):1415-1426
pubmed: 30349037
Oncogene. 2005 Feb 3;24(6):1011-20
pubmed: 15592500
J Immunol. 2007 Jun 1;178(11):6867-75
pubmed: 17513735
J Clin Invest. 2020 Mar 2;130(3):1199-1216
pubmed: 32015230
Mol Endocrinol. 2011 Feb;25(2):315-26
pubmed: 21193559
Biochem Biophys Res Commun. 2006 Dec 15;351(2):571-6
pubmed: 17069754
Biotechnol Adv. 2016 Dec;34(8):1427-1441
pubmed: 27845258
Hum Gene Ther. 2021 Oct;32(19-20):1029-1043
pubmed: 34662227
Cancer Metab. 2018 Dec 03;6:18
pubmed: 30524726
J Hematol Oncol. 2019 Aug 28;12(1):86
pubmed: 31462327
Cell Cycle. 2011 Dec 15;10(24):4208-16
pubmed: 22033146
Cancer Res. 2013 Sep 15;73(18):5657-68
pubmed: 23903958
Adv Drug Deliv Rev. 2017 Apr;113:24-48
pubmed: 27497513
Cancer Cell. 2012 Mar 20;21(3):418-29
pubmed: 22439937
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
J Immunother Cancer. 2018 Nov 6;6(Suppl 1):115
pubmed: 30400822
Genome Res. 2020 Jun;30(6):803-813
pubmed: 32661091
Sci Adv. 2020 Jan 31;6(5):eaay4458
pubmed: 32064351
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32601081
Int J Cancer. 1994 Apr 1;57(1):104-10
pubmed: 7908658
Target Oncol. 2018 Feb;13(1):89-98
pubmed: 29188408
Sci Adv. 2021 Apr 30;7(18):
pubmed: 33931442
Elife. 2019 Dec 16;8:
pubmed: 31841108
Nat Rev Immunol. 2018 Mar;18(3):204-211
pubmed: 29398707
Immunity. 2014 Nov 20;41(5):830-42
pubmed: 25517615
Nat Rev Clin Oncol. 2011 Mar 01;8(4):210-21
pubmed: 21364524
Theranostics. 2020 Jul 9;10(19):8721-8743
pubmed: 32754274
Cancer Discov. 2021 May;11(5):1067-1081
pubmed: 33504580
Blood. 2006 Oct 1;108(7):2280-9
pubmed: 16757686
Blood Cancer J. 2015 Sep 25;5:e350
pubmed: 26407235
PLoS One. 2012;7(2):e30753
pubmed: 22363483
Front Immunol. 2020 Dec 14;11:594609
pubmed: 33381115
Cancer Immunol Res. 2015 Apr;3(4):412-23
pubmed: 25691328
Blood. 2000 Mar 1;95(5):1588-93
pubmed: 10688812
Biochem Pharmacol. 2013 May 15;85(10):1424-32
pubmed: 23466421
Oncol Lett. 2017 Sep;14(3):2611-2620
pubmed: 28927027
BMC Cancer. 2018 Mar 27;18(1):335
pubmed: 29587663
Nat Cancer. 2021 Jan;2(1):83-97
pubmed: 35121889
Front Oncol. 2020 Aug 18;10:1488
pubmed: 33014790
J Biol Chem. 1982 Jul 10;257(13):7847-51
pubmed: 7085651
Clin Cancer Res. 2011 Apr 1;17(7):1998-2005
pubmed: 21447719
J Immunother. 2010 Oct;33(8):780-8
pubmed: 20842059
Cell Stem Cell. 2018 Mar 1;22(3):454-467.e6
pubmed: 29337182
Cancer Res. 2013 Mar 15;73(6):1993-2002
pubmed: 23333938
Nature. 2006 Dec 21;444(7122):1083-7
pubmed: 17183323
Nat Rev Cancer. 2018 Jul;18(7):407-418
pubmed: 29692415
Immunity. 2019 Apr 16;50(4):924-940
pubmed: 30995507
Br J Cancer. 2014 Jan 7;110(1):172-82
pubmed: 24178759
Nat Med. 2014 Jul;20(7):769-77
pubmed: 24859528
Mol Cell Biol. 2011 Oct;31(19):3963-74
pubmed: 21807895
Nat Biotechnol. 2014 Aug;32(8):760-72
pubmed: 25093883
Lancet. 2019 Nov 23;394(10212):1929-1939
pubmed: 31590988
Nat Rev Immunol. 2021 Mar;21(3):151-161
pubmed: 32839570
Cancer Res Treat. 2019 Jul;51(3):861-875
pubmed: 30282451
Proc Natl Acad Sci U S A. 2011 Feb 15;108(7):2909-14
pubmed: 21282607
Clin Cancer Res. 2010 Feb 15;16(4):1191-205
pubmed: 20145179
Oncogene. 2014 Mar 6;33(10):1265-73
pubmed: 23524582
Endocr Relat Cancer. 2003 Jun;10(2):179-86
pubmed: 12790780
Nature. 2011 Jun 08;475(7355):222-5
pubmed: 21654748
Clin Cancer Res. 2000 Aug;6(8):3056-61
pubmed: 10955784
Nat Immunol. 2017 Sep;18(9):985-994
pubmed: 28714978
Cell Host Microbe. 2009 Jan 22;5(1):23-34
pubmed: 19154985
Cancer Treat Rev. 2011 Feb;37(1):63-74
pubmed: 20570444
Cell. 2019 Feb 21;176(5):998-1013.e16
pubmed: 30712876
Biomaterials. 2020 Jul;247:119984
pubmed: 32278214
Nature. 2017 Mar 16;543(7645):428-432
pubmed: 28273064
Adv Drug Deliv Rev. 2016 Feb 1;97:41-55
pubmed: 26743193
Front Immunol. 2018 Feb 26;9:340
pubmed: 29535721
Cancer Res. 2011 Oct 1;71(19):6143-52
pubmed: 21852386
Immunol Rev. 2021 Mar;300(1):220-236
pubmed: 33565148
Cell Stem Cell. 2018 Dec 6;23(6):882-897.e11
pubmed: 30344100
Mol Cancer. 2021 Oct 11;20(1):131
pubmed: 34635121
Biomaterials. 2018 May;163:185-197
pubmed: 29477032
Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):4129-34
pubmed: 21325052
Cell Host Microbe. 2011 Oct 20;10(4):324-35
pubmed: 22018233
Adv Exp Med Biol. 2020;1234:71-86
pubmed: 32040856
J Immunol. 2008 May 1;180(9):5916-26
pubmed: 18424711
J Hematol Oncol. 2021 Apr 6;14(1):55
pubmed: 33823905
J Control Release. 2015 Jul 10;209:101-9
pubmed: 25916496
ACS Med Chem Lett. 2017 Jul 27;8(8):814-819
pubmed: 28835794
J Immunol. 2005 Apr 15;174(8):4670-7
pubmed: 15814691
Expert Opin Ther Targets. 2013 Jul;17(7):743-60
pubmed: 23651053
Am Sci. 1972 Jan-Feb;60(1):56-63
pubmed: 4332766
Nat Rev Immunol. 2020 Nov;20(11):651-668
pubmed: 32433532
Mol Cancer. 2019 Dec 5;18(1):177
pubmed: 31805946
Trends Immunol. 2020 Aug;41(8):652-664
pubmed: 32654925
Cell Commun Signal. 2020 Apr 7;18(1):59
pubmed: 32264958
Nat Med. 2020 Jan;26(1):39-46
pubmed: 31873309
Cancer Res. 2005 Oct 1;65(19):8690-7
pubmed: 16204037
iScience. 2021 Aug 24;24(9):103020
pubmed: 34522863
Ann Oncol. 2018 Jul 1;29(7):1561-1568
pubmed: 29726923
J Clin Invest. 2021 Mar 15;131(6):
pubmed: 33720045
PLoS One. 2013 Oct 30;8(10):e77992
pubmed: 24205057
Trends Immunol. 2016 Mar;37(3):208-220
pubmed: 26858199
Cancer Biol Med. 2014 Mar;11(1):1-19
pubmed: 24738035
Science. 2013 Nov 22;342(6161):971-6
pubmed: 24264990
Clin Genitourin Cancer. 2019 Apr;17(2):e306-e313
pubmed: 30598361
Oncotarget. 2017 Jan 3;8(1):1725-1736
pubmed: 27965457
J Biosci. 2015 Jun;40(2):269-79
pubmed: 25963256
Nature. 2016 May 18;533(7604):493-498
pubmed: 27225120
Nat Commun. 2019 Aug 21;10(1):3763
pubmed: 31434891
Ann Oncol. 2017 Jun 01;28(6):1368-1379
pubmed: 28368458
Science. 2018 Feb 2;359(6375):592-597
pubmed: 29420293
Cancer Commun (Lond). 2023 May;43(5):525-561
pubmed: 37005490
Nat Rev Immunol. 2020 Mar;20(3):173-185
pubmed: 31676858
Cell. 2017 Jul 27;170(3):548-563.e16
pubmed: 28753429
Cancer Chemother Pharmacol. 2017 Jun;79(6):1169-1177
pubmed: 28451833
Science. 2015 Nov 27;350(6264):1079-84
pubmed: 26541610
Front Vet Sci. 2019 Apr 09;6:106
pubmed: 31111038
Nat Rev Cancer. 2019 Nov;19(11):651-661
pubmed: 31530936
Cancer Res. 2008 Nov 15;68(22):9107-11
pubmed: 19010878
Cancer J. 2015 Mar-Apr;21(2):49-55
pubmed: 25815843
Immunother Adv. 2021 Dec 20;2(1):ltab025
pubmed: 35265944
Signal Transduct Target Ther. 2021 Apr 23;6(1):153
pubmed: 33888679
Cell. 2020 Oct 15;183(2):363-376.e13
pubmed: 33007267
J Leukoc Biol. 2003 Apr;73(4):482-92
pubmed: 12660223
Trends Mol Med. 2017 May;23(5):393-410
pubmed: 28341301
Genes Cancer. 2011 Dec;2(12):1106-16
pubmed: 22866202
Nat Rev Immunol. 2017 Jun;17(6):349-362
pubmed: 28436425
Trends Cell Biol. 2017 Nov;27(11):863-875
pubmed: 28734735
Cell Rep. 2018 Sep 25;24(13):3528-3538
pubmed: 30257213
ChemMedChem. 2012 Feb 6;7(2):311-7
pubmed: 22052811
Mol Cell. 2021 Sep 16;81(18):3760-3774
pubmed: 34547237
Cancer Res. 2020 Mar 1;80(5):1130-1142
pubmed: 31848194
Acta Biochim Biophys Sin (Shanghai). 2018 Jan 1;50(1):121-132
pubmed: 29190313
Biotechnol Bioeng. 2020 Apr;117(4):1204-1229
pubmed: 31840797
J Biol Chem. 1983 Oct 10;258(19):11442-5
pubmed: 6311812
Cancer Discov. 2018 Feb;8(2):196-215
pubmed: 29101162
Cell Metab. 2014 May 6;19(5):795-809
pubmed: 24726384
Antioxid Redox Signal. 2009 Sep;11(9):2317-31
pubmed: 19243234
Nat Rev Cancer. 2020 Nov;20(11):662-680
pubmed: 32753728
EMBO J. 2020 Feb 3;39(3):e102525
pubmed: 31919869
Oncogene. 2014 Nov 6;33(45):5225-37
pubmed: 24336328
Invest New Drugs. 2019 Feb;37(1):118-126
pubmed: 29995286
Proc Natl Acad Sci U S A. 2019 Feb 5;116(6):2210-2219
pubmed: 30659155
FASEB J. 2019 Mar;33(3):3481-3495
pubmed: 30452881
J Cell Biochem. 2007 Jul 1;101(4):937-49
pubmed: 17171643
Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):609-618
pubmed: 30587582
Cancer Res. 2006 Sep 15;66(18):9290-8
pubmed: 16982774
Oncotarget. 2017 May 10;8(39):65090-65099
pubmed: 29029414
J Clin Med. 2019 Jan 08;8(1):
pubmed: 30626115
Int J Mol Sci. 2019 Feb 14;20(4):
pubmed: 30769852
Commun Biol. 2020 Mar 17;3(1):128
pubmed: 32184441
Biosens Bioelectron. 2015 Jan 15;63:218-231
pubmed: 25105943
Cell Metab. 2016 Nov 8;24(5):701-715
pubmed: 27773694
Blood. 2009 Jun 18;113(25):6392-402
pubmed: 19377047
Int J Cancer. 1995 Mar 29;61(1):35-9
pubmed: 7705931
J Angiogenes Res. 2010 Jun 22;2:10
pubmed: 20569499
Nature. 2019 Oct;574(7779):575-580
pubmed: 31645732
J Cell Biochem. 2016 Jun;117(6):1279-87
pubmed: 26774024
J Immunother Cancer. 2020 Dec;8(2):
pubmed: 33335026
Ann N Y Acad Sci. 1976;277(00):332-8
pubmed: 1069552
Neoplasia. 2017 Oct;19(10):848-855
pubmed: 28923537
Front Cell Dev Biol. 2020 Oct 15;8:569219
pubmed: 33178688
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Cell Stem Cell. 2016 Jun 2;18(6):827-838
pubmed: 27212702
Prostate. 2016 Oct;76(14):1257-70
pubmed: 27324746
J Immunol. 2002 Nov 15;169(10):5392-5
pubmed: 12421911
Pharmacol Ther. 2016 Jul;163:94-108
pubmed: 27063403
Biomark Res. 2022 Apr 13;10(1):22
pubmed: 35418152
Nat Commun. 2020 Sep 24;11(1):4835
pubmed: 32973173
Nat Rev Cancer. 2021 Feb;21(2):71-88
pubmed: 33214692
Sci Transl Med. 2020 Mar 18;12(535):
pubmed: 32188726
J Exp Med. 1997 Feb 3;185(3):393-403
pubmed: 9053440
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80
pubmed: 20385810
Nature. 2020 Apr;580(7804):530-535
pubmed: 32322062
Cell. 2018 Dec 13;175(7):1972-1988.e16
pubmed: 30550791
Annu Rev Pathol. 2021 Jan 24;16:223-249
pubmed: 33197221
Mol Cell. 2018 Nov 15;72(4):650-660.e8
pubmed: 30392930
Cell. 2020 Oct 29;183(3):786-801.e19
pubmed: 33125893
Lab Chip. 2019 Jan 29;19(3):369-386
pubmed: 30644496
Immunol Rev. 2017 Mar;276(1):97-111
pubmed: 28258697
Nat Rev Clin Oncol. 2021 Apr;18(4):244-256
pubmed: 33277626
Oncologist. 2019 Oct;24(10):1309-e983
pubmed: 31213500
PLoS One. 2014 Oct 01;9(10):e108887
pubmed: 25272271
J Vet Intern Med. 2021 Jan;35(1):415-429
pubmed: 32542733
Invest New Drugs. 2020 Jun;38(3):800-811
pubmed: 31297636
J Med Chem. 2011 Mar 24;54(6):1599-612
pubmed: 21332213
J Hematol Oncol. 2019 Dec 29;12(1):142
pubmed: 31884964
Cytokine. 2008 Oct;44(1):191-200
pubmed: 18790652
Int Immunol. 2016 Nov;28(11):547-557
pubmed: 27543653
Eur J Immunol. 2008 Sep;38(9):2438-50
pubmed: 18792400
IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1-441
pubmed: 23189750
Nat Commun. 2015 Oct 27;6:8692
pubmed: 26503691
Immunol Rev. 2021 Jul;302(1):259-272
pubmed: 34013544
Am J Pathol. 2020 May;190(5):934-946
pubmed: 32112719
Neurosurgery. 2004 Dec;55(6):1410-9; discussion 1419
pubmed: 15574223
Lancet. 2017 Oct 21;390(10105):1833-1842
pubmed: 28855077
Transfus Med Rev. 2017 Jan;31(1):36-44
pubmed: 27523957
Nat Med. 2012 Sep;18(9):1394-400
pubmed: 22863785
Int J Mol Sci. 2017 Jan 27;18(2):
pubmed: 28134810
Gut. 2020 Oct;69(10):1867-1876
pubmed: 32759302
Proc Natl Acad Sci U S A. 2004 Nov 9;101(45):15949-54
pubmed: 15520367
Am J Pathol. 1997 Feb;150(2):409-15
pubmed: 9033256
Carcinogenesis. 2009 Dec;30(12):1979-86
pubmed: 19793799
Science. 2017 Sep 15;357(6356):1156-1160
pubmed: 28912244
J Immunol. 2014 Jan 15;192(2):782-91
pubmed: 24337741
Immunology. 2017 Oct;152(2):175-184
pubmed: 28621843
Mol Ther Nucleic Acids. 2019 Mar 1;14:80-89
pubmed: 30583098
J Am Chem Soc. 2021 Nov 10;143(44):18536-18547
pubmed: 34661406
Immunity. 2015 Feb 17;42(2):344-355
pubmed: 25680274
Biochim Biophys Acta. 2014 Aug;1846(1):238-46
pubmed: 25026312
Cancer Med. 2019 Sep;8(11):5148-5157
pubmed: 31347292
Nat Rev Clin Oncol. 2021 Jan;18(1):9-34
pubmed: 32710082
Trends Biochem Sci. 2019 Feb;44(2):153-166
pubmed: 30473428
Clin Cancer Res. 2021 Feb 1;27(3):689-703
pubmed: 33122346
FEBS Lett. 2004 Sep 10;574(1-3):37-41
pubmed: 15358536
J Immunol. 2007 Mar 15;178(6):3612-9
pubmed: 17339458
Cell. 2016 Feb 11;164(4):681-94
pubmed: 26853473
PLoS One. 2014 Mar 11;9(3):e90353
pubmed: 24618589
Cell. 2018 Feb 22;172(5):1022-1037.e14
pubmed: 29429633